PubMed Trending Research Digest — July 15, 2026

Automated digest · 100 articles · 15 research areas · July 15, 2026

Overview

This week’s digest is dominated by a “precision + timing” theme in oncology and immunology. Multiple studies use high-resolution molecular readouts—especially ctDNA and spatial/multi-omics profiling—to detect resistance early and align therapy to evolving tumor biology (e.g., mutation emergence timing in hormone receptor–positive breast cancer, ctDNA tumor fraction for immunotherapy selection, and spatial immune signatures predicting response in resectable NSCLC). In parallel, mechanistic work is clarifying how to modulate immune failure: FAD acts as an endogenous brake on cGAS/RIG-I sensing, MEK-dependent bioenergetic stress drives CD8 exhaustion, and nerve-associated tumor states promote immune evasion via defined signaling axes.

Across non-oncology areas, the strongest signals are (1) biomarker standardization/validation and (2) circuit- and tissue-level mechanisms. In neurodegeneration, blood-based and imaging biomarkers are being stress-tested for specificity (e.g., plasma AD markers vs prion disease) while Alzheimer-related therapeutic targeting continues (tau-aggregation via OGA inhibition; amyloid PET Centiloid harmonization). In cardiometabolic disease, real-world and pharmacovigilance studies continue to refine the safety and clinical utility of GLP-1–based therapies (including optic neuropathy risk and insulin de-escalation), while obesity and metabolic risk are linked to brain aging. Finally, advances in spatial omics and genome/epigenome tools (stress granule nucleic acid composition, chromatin immunoconversion sequencing, cohesin and PRC2 regulation) reinforce a broader shift toward mapping biology in its native context—cells, tissues, and time.

---

Cancer precision oncology (biomarkers, ctDNA, multi-omics, resistance)

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

The phase I TRAVERSE trial studied the allogeneic CD70-targeted CAR T-cell product ALLO-316 in patients with advanced clear cell renal cell carcinoma (ccRCC) resistant to immune checkpoint inhibitors and VEGFR-targeted therapy. ALLO-316 was designed to resist immune rejection by targeting and eliminating patients’ CD70+ alloreactive T cells, and the trial evaluated ALLO-316 with lymphodepletion using a modified 3+3 dose-escalation approach with fludarabine/cyclophosphamide. This provides early clinical evidence for an allogeneic, CD70-directed CAR T strategy in refractory ccRCC where effective post–ICI/targeted options are limited.

Srour SA, Chahoud J, Drakaki A et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials.

This review synthesized evidence from randomized controlled clinical trials (≥30 patients) of topical and systemic therapies for atopic dermatitis, focusing on baseline disease severity and patient burden across treatment studies. It identified how trial populations differ in baseline severity and burden, which can influence which patients are most likely to benefit from specific advanced topical agents (e.g., crisaborole, roflumilast, ruxolitinib, tapinarof) and systemic therapies (e.g., abrocitinib, baricitinib, dupilumab, lebrikizumab). The work supports more phenotype- and severity-informed selection of topical versus systemic treatments in clinical practice and trial design.

Gooderham MJ, Hong HC, Lynde C et al. · Dermatology and therapy · (2026) · View on PubMed ↗

African swine fever virus MGF_110-3L and MGF_110-4L signal TLR2-mediated lethal inflammation.

The study investigated how African swine fever virus (ASFV) proteins MGF_110-3L and MGF_110-4L drive systemic inflammation in porcine immune cells. Using single-cell RNA sequencing of porcine PBMCs and mechanistic assays, the authors found that both proteins bind Toll-like receptor 2 (TLR2) and signal via TLR2/TLR1 and TLR2/TLR6 heterocomplexes, with CD14 enhancing ligand recognition and amplification, leading to lethal inflammatory responses. These findings identify a specific viral–innate immune axis (MGF_110-3L/4L–TLR2) that could be targeted to mitigate ASFV-associated cytokine storm and immunopathology.

Wang Y, Xia T, Shao YH et al. · Protein & cell · (2026) · View on PubMed ↗

Metabolic syndrome is associated with accelerated brain aging.

This UK Biobank study examined whether metabolic syndrome (MetS) is associated with accelerated brain aging in 27,375 participants aged 40–70 years. MetS (defined by ≥3 of central adiposity, hypertension, dyslipidemia, hypertriglyceridemia, and hyperglycemia) was linked to increased brain age gap (BAG), with brain age estimated from MRI-based machine learning using 1079 imaging phenotypes and plasma metabolite profiling. The results suggest MetS may contribute to neurobiological aging processes relevant to dementia risk and could motivate metabolic risk reduction to slow brain aging.

Dove A, Wang J, Yang R et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Medical Treatments for Obesity: What Does the Future Have in Store?

This narrative review assessed the future landscape of obesity pharmacotherapy by surveying evidence from 2021–2026 phase 2 and 3 trials of newer anti-obesity drugs. It emphasizes that modern obesity treatments aim not only for weight loss but also for improvements in obesity-related complications, supporting a shift toward phenotype-guided, complication-centric care. Clinically, this frames how emerging therapies (including next-generation agents) may be selected based on patient comorbidities and treatment goals beyond BMI.

Bassatne A, Rizo I · The Journal of clinical endocrinology and metabolism · (2026) · View on PubMed ↗

Loss of E3 Ubiquitin Ligase RINES via CpG Methylation Relieves Suppression of STAT3 and MYC, Facilitating Multiple Tumorigeneses.

The study investigated the role of the E3 ubiquitin ligase RINES (RNF proteins) in cancer by identifying tumor-specific epigenetic silencing mechanisms. Across multiple common cancer types, promoter CpG methylation led to loss of RINES, relieving suppression of STAT3 and MYC and facilitating multiple tumorigeneses, with functional validation showing RINES inhibits tumor growth in vitro and in vivo. This positions CpG methylation–mediated RINES loss as a mechanistic driver and potential biomarker/therapeutic target in cancers with STAT3/MYC pathway activation.

Li L, Ng KM, Shu X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.

This retrospective real-world study compared progression-free survival in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients treated with daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus bortezomib, lenalidomide, and dexamethasone (VRd). Adult patients initiating DVRd-DR/R (daratumumab with VRd plus DR or R maintenance) were compared with those initiating VRd-R between 1 January 2020 and 30 June 2022 across 10 US sites. The findings inform how the quadruplet DVRd regimen performs outside clinical trials and may guide frontline treatment decisions for transplant-eligible NDMM.

Tan CR, Gordan L, Richter J et al. · Future oncology (London, England) · (2026) · View on PubMed ↗

Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network.

This AIDA Network real-world analysis evaluated canakinumab effectiveness in familial Mediterranean fever (FMF) patients, focusing on achieving complete clinical-laboratory control. Among 158 FMF patients treated with canakinumab, complete clinical-laboratory response occurred in 45.6% at 3 months and 58.6% at 12 months, with 55.2% at last follow-up, based on both retrospective and prospective registry data. The results support canakinumab as an effective option for attaining full control of FMF manifestations and normalization of inflammatory markers in routine care.

Vitale A, Caggiano V, Sbalchiero J et al. · Rheumatology (Oxford, England) · (2026) · View on PubMed ↗

In vivo-directed evolution identifies AAV-WM04 as a next-generation vector for potent and sustained hearing restoration in DFNB9.

This study used in vivo-directed evolution to develop and test a next-generation AAV2-derived gene therapy capsid, AAV-WM04, for hearing restoration in DFNB9. In adult mouse cochlea, iterative selection from a randomized AAV2 capsid library (with 9-amino-acid insertions) identified AAV-WM04 as having superior packaging efficiency and strong inner hair cell (IHC) tropism, achieving near-complete IHC transduction across the cochlear axis at low doses. The work advances capsid engineering as a route to more potent and sustained inner ear gene delivery for DFNB9.

Tao Y, Chu C, Cheng Z et al. · Molecular therapy : the journal of the American Society of Gene Therapy · (2026) · View on PubMed ↗

Evaluation of a serum protein signature as monitoring biomarker for Duchenne muscular dystrophy in a long-term clinical trial with corticosteroids.

This study evaluated whether a serum protein signature can serve as a monitoring biomarker for functional outcomes in boys with Duchenne muscular dystrophy (DMD) enrolled in the FOR-DMD trial receiving daily versus intermittent corticosteroids. Using the aptamer-based SomaScan platform to profile 1500 proteins, the authors assessed longitudinal associations between serum protein levels and motor function measures such as Rise from the Floor Velocity (RFV) and 10-Meter Run/Walk. If validated, the protein signature could enable more responsive, trial-relevant monitoring of disease function under corticosteroid regimens in DMD.

Degan C, Tobin RA, de Vries SI et al. · Skeletal muscle · (2026) · View on PubMed ↗

Multi-omics and spatial proteomic profiling reveal novel AGXT2- PYCR3- macrophages and their phenotypes in metabolic dysfunction-associated steatotic liver disease.

The study investigated MASLD (metabolic dysfunction-associated steatotic liver disease) liver immune microenvironments in human samples using integrative multi-omics, CyTOF immunophenotyping, and spatial proteomics, with in vitro validation and mass spectrometry of sorted cell populations to define AGXT2–PYCR3 macrophage phenotypes. It identified novel AGXT2-PYCR3 macrophage populations and characterized their spatial/phenotypic signatures associated with metabolic dysfunction in MASLD. These findings suggest AGXT2 and PYCR3 macrophage programs as potential mechanistic targets and biomarkers for early-to-intermediate MASLD intervention.

Lv T, Dai H, Zhang S et al. · Genome medicine · (2026) · View on PubMed ↗

Multi-omics fusion with machine learning enables robust prediction of treatment response in ovarian cancer for precision population health.

The study developed OMICS-FUSE, an early-fusion multi-omics machine-learning model integrating proteomic, transcriptomic, and methylomic data to predict treatment response in ovarian cancer patients. Using an early-fusion Random Forest approach, the model achieved strong predictive performance (AUC 0.939; accuracy 0.896; F1 0.939) and, despite similar or better accuracy than best single-omics models, provided a better accuracy–F1 balance, with SHAP highlighting key features (details truncated). This multi-omics framework supports more robust precision oncology response prediction in heterogeneous ovarian cancer populations.

Chen J, Mao T, Yang Y et al. · NPJ digital medicine · (2026) · View on PubMed ↗

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

This single-institution randomized phase 2 trial studied CPX-351 versus CLAG-M (cladribine, cytarabine, G-CSF, mitoxantrone) in 60 untreated medically unfit adults with acute myeloid leukemia (AML) and a TRM score ≥13.1 (68% with ECOG 3–4). CPX-351 was compared against standard-dose CLAG-M with 3-month overall survival as the primary endpoint and response rate and other outcomes as key secondary endpoints. The trial is clinically significant because it tests whether CPX-351 can improve early survival in a high-risk, treatment-ineligible AML population where optimal therapy remains uncertain.

Halpern AB, Othus M, Percival MM et al. · Leukemia · (2026) · View on PubMed ↗

PIAS1-mediated GSK3β SUMOylation exacerbates tauopathy and cognitive deficits in Alzheimer’s disease models.

This study investigated PIAS1 as a SUMO E3 ligase that drives tau pathology using a bimolecular fluorescence complementation (BiFC) assay to monitor Tau-Tau aggregation in Alzheimer’s disease models, alongside genetic association analyses in the UK Biobank. PIAS1-mediated GSK3β SUMOylation exacerbated tauopathy and cognitive deficits, and PIAS1 SNPs (rs8036154, rs112677781) were associated with reduced AD risk. These findings are scientifically significant because they identify a PIAS1–GSK3β SUMOylation axis as a mechanistic contributor to tau-driven neurodegeneration and a potential therapeutic target.

Qiu Y, Wu S, Zhong Y et al. · Molecular psychiatry · (2026) · View on PubMed ↗

Astrocytic lipid dysregulation as an early driver of neurodegeneration.

This review synthesized evidence on how astrocytic lipid dysregulation acts as an early driver of neurodegeneration across multiple disorders, focusing on astrocyte roles in cholesterol synthesis, fatty-acid detoxification, lipid droplet dynamics, and redox homeostasis. The key conclusion is that disturbances in astrocyte lipid homeostasis can precede overt neuronal degeneration in diseases including Alzheimer’s, Parkinson’s, ALS, frontotemporal dementia, and Huntington disease. The work is significant because it reframes astrocytes as metabolic regulators whose lipid pathways may offer early biomarkers and intervention points for neurodegenerative disease.

Kim WS, Halliday GM · Nature reviews. Neurology · (2026) · View on PubMed ↗

Breakthrough drugs in the treatment of hypertension-related disease.

This article reviewed advances and ongoing challenges in treating hypertension-related disease, emphasizing the population-level burden of hypertension and the clinical barriers to effective blood pressure control in Japan. It highlights that suboptimal control is driven by factors such as clinical inertia, poor adherence, and difficulty selecting appropriate antihypertensive therapies. The significance lies in guiding future strategies to improve long-term cardiovascular, cerebrovascular, and renal outcomes by addressing implementation gaps in hypertension management.

Hoshide S, Mogi M, Shibata S et al. · Hypertension research : official journal of the Japanese Society of Hypertension · (2026) · View on PubMed ↗

Macrophage CCRL2 promotes NLRP3 inflammasome activation to exacerbate atherosclerosis.

This study examined how macrophage CCRL2 influences inflammatory signaling in atherosclerosis by promoting NLRP3 inflammasome activation. CCRL2 expression in plaque macrophages was reported to increase during atherosclerotic progression and to enhance NLRP3 inflammasome-driven inflammation, thereby exacerbating atherosclerosis. The findings are significant because CCRL2 may represent a macrophage-targetable regulator of NLRP3 inflammasome activity for more specific anti-inflammatory therapies in atherosclerotic disease.

Cai Q, Duan Z, Yang Z et al. · Cellular & molecular immunology · (2026) · View on PubMed ↗

Identification of a sequence element regulating H3K9 methylation at the ap2-g locus in Plasmodium falciparum.

This work studied cis-regulatory control of H3K9 methylation at the Plasmodium falciparum ap2-g locus during erythrocytic-stage differentiation into gametocytes. The authors identified the URE-G element as required for high H3K9 methylation at ap2-g, and deleting URE-G reduced H3K9me3, leading to AP2-G activation and increased gametocyte formation. The study is significant because it clarifies how heterochromatin silencing is lifted to regulate parasite cell fate, informing malaria transmission biology.

Nakashima M, Iwanaga S, Mori T · Scientific reports · (2026) · View on PubMed ↗

Epigenetic signatures mark early peripheral human B lineage bifurcation and differential transcriptional profiles in mature populations.

This study profiled early human B cell lineage bifurcation by comparing epigenetic and transcriptional states of transitional T1, T2Mhi, and T2Mlo cells from adult and cord blood using bulk and single-cell ATAC-seq, CUT&RUN, RNA-seq, and CITE-seq. It identified accessible chromatin domains that distinguish T2Mhi versus T2Mlo trajectories and showed that epigenetic signatures persist as T2Mlo differentiates into naïve B cells, with memory and marginal zone B cells retaining related epigenetic features. The significance is that it maps epigenetic determinants of human B cell fate decisions, providing mechanistic markers of how early bifurcation shapes mature immune repertoires.

Dionisi C, Kelly A, Pitcher MJ et al. · Nature communications · (2026) · View on PubMed ↗

Genetic or pharmacological inhibition of hepatic TMEM141 attenuates MASH and fibrosis via the ROS-HNF4α signaling pathway.

This study investigated whether hepatic TMEM141 regulates metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis by combining genetic and pharmacological inhibition approaches with mechanistic ROS–HNF4α pathway analysis. Hepatic TMEM141 was reduced in MASLD/MASH patients and mouse models, and hepatocyte TMEM141 loss protected against HFCF diet-induced MASLD/MASH while hepatic overexpression worsened disease, with microRNA-149 implicated in TMEM141 downregulation. The findings are significant because they position TMEM141 as a druggable hepatic regulator of MASH progression via ROS-HNF4α signaling.

Wang J, Chen CL, Gopoju R et al. · Nature communications · (2026) · View on PubMed ↗

A small nucleolar RNA dictates the structure and function of translating ribosomes in Leishmania.

This study examined how a specific small nucleolar RNA (snoRNA) controls ribosome structure and function in Leishmania by mapping the landscape of 2’-O-methylation and determining stage-regulated modifications. Cytosine base-editing of the snoRNA guiding the stage-regulated 2’-O-methylation (Am479) prevented detection of ribosomes lacking that modification, and cryo-EM structures were used to define how the modification shapes translating ribosomes. The significance is that it identifies an essential snoRNA-guided rRNA modification as a structural and functional requirement for translation in a parasite with distinct life stages.

Rajan KS, Aryal S, Murugeshan S et al. · Nature communications · (2026) · View on PubMed ↗

Oncogenic Ras drives EED degradation and PRC2 dysfunction to promote aggressive squamous cell carcinoma.

This study investigated how oncogenic Ras alters Polycomb repressive complex 2 (PRC2) function in squamous cell carcinoma by focusing on EED degradation and loss of PRC2 activity. It found that despite elevated EZH2, PRC2-catalyzed H3K27me3 was markedly reduced in human SCC and mouse models, and mechanistically oncogenic Ras signaling promoted degradation of the PRC2 subunit EED, destabilizing PRC2. The significance is that it reveals a Ras–EED–PRC2 axis driving aggressive SCC, suggesting that restoring PRC2/H3K27me3 regulation could be a therapeutic strategy.

Li MY, Houser A, Cheema P et al. · Nature communications · (2026) · View on PubMed ↗

ProLM: a plasma proteomics pretrained model for the general population.

The study developed and evaluated ProLM, a BERT-based plasma proteomics pretrained model using 15,499 relatively healthy UK Biobank participants, to learn general protein-expression relationships and predict chronic disease risk. After disease-specific fine-tuning, ProLM-derived proteomic risk scores outperformed Age+Sex for 16/16 diseases, the ASCVD risk equation for 14/16 diseases, and a 35-variable clinical PANEL score for 11/16 diseases. This suggests that large-scale pretrained plasma proteomics models can improve multi-disease risk stratification and provide interpretable protein drivers for clinical prediction.

Qiu S, Zhao M, Chen X et al. · Nature communications · (2026) · View on PubMed ↗

TAF15 amyloids propagate via defined motifs in a prion-like fashion.

The study investigated how the RNA-binding protein TAF15 aggregates and propagates in a prion-like manner, using recombinant TAF15 fibrils, FTLD patient brain-derived aggregates, and a cellular TAF15 biosensor. Recombinant fibrils and patient-derived pathological aggregates selectively seeded TAF15 biosensor cells, while the related protein FUS did not seed TAF15 aggregation, indicating a cross-seeding barrier. These findings define motif-dependent, prion-like determinants of TAF15 propagation and support mechanistic targets to block spread in TAF15-associated FTLD.

Konstantoulea K, Gadhe L, Goodavish F et al. · Nature communications · (2026) · View on PubMed ↗

Nuclear condensates formed by truncated mutant NEK1s impede ribosomal RNA biogenesis and drive motor dysfunction.

The study examined ALS-related nonsense mutations in NEK1 by characterizing three truncated NEK1 mutant forms and their effects on subcellular localization, nucleolar/nuclear condensate formation, and ribosomal RNA biogenesis in cellular models. The truncated NEK1 mutants translocated to the nucleus, localized to nucleoli, formed liquid-like nucleoplasmic foci, and impeded ribosomal RNA biogenesis, leading to motor dysfunction phenotypes. This links NEK1 truncation-driven nuclear condensates to impaired ribosome biogenesis as a mechanistic pathway for ALS.

Wang Y, Hu W, Huang R et al. · Nature communications · (2026) · View on PubMed ↗

ERG preserves endothelial identity to limit atherosclerosis.

The study tested the role of the endothelial ETS transcription factor ERG in atherosclerosis by using inducible endothelial Erg deletion in hypercholesterolemic mice and analyzing plaque cell states with lineage tracing and single-cell transcriptomics. ERG loss increased plaque burden and drove endothelial dedifferentiation with mesenchymal fate acquisition, migration, and expansion of EndMT cells within plaques. These results establish ERG as a key protector of endothelial identity and suggest that preserving ERG-dependent programs could limit EndMT-driven atheroprogression.

Botts SR, Scipione CA, Schulz K et al. · Nature communications · (2026) · View on PubMed ↗

A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.

The study created and evaluated a multimodal tumor profiling resource for women with high-grade serous ovarian cancer, integrating blood, single-cell and bulk tumor tissue, and malignant ascites using up to 11 technologies (DNA, RNA, protein, and functional assays) within a four-week turnaround. Molecular profiling changed hypothetical treatment recommendations for 76% of patients and multi-omics-guided maintenance therapy was associated with prolonged overall survival in a subset. This supports the clinical feasibility of rapid, comprehensive multi-omics profiling to address chemotherapy-driven heterogeneity and enable more personalized treatment strategies.

Jacob F, Wegmann R, Ficek-Pascual J et al. · Nature communications · (2026) · View on PubMed ↗

Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma.

The study investigated how hepatocellular carcinoma (HCC) alters tissue-resident regulatory T cells (Tregs) by focusing on Nrf2-dependent metabolic reprogramming in the lactate-rich tumor microenvironment. HCC-infiltrating Tregs activated the Nrf2 pathway in response to lactate, coupling redox homeostasis with mitochondrial function to promote Treg metabolic activity and accumulation, whereas non-tumoral liver Tregs were metabolically inert and prone to apoptosis. This identifies Nrf2-mediated metabolic control as a driver of Treg enrichment in HCC and a potential therapeutic lever to enhance anti-tumor immunity.

Perpiñán E, Sompairac N, Marin Correa D et al. · Nature communications · (2026) · View on PubMed ↗

Restoring the CD226 in CD8+T cells overcomes TIGIT-refractory immunity in HER2+ breast cancer.

The study analyzed immune mechanisms of immune checkpoint blockade refractoriness in HER2+ breast cancer by integrating single-cell transcriptomics from untreated human and murine tumors with functional co-culture assays and in vivo perturbations, including an anti-HER2 non-sensitive mouse model and a neoadjuvant non-pCR patient cohort. It identified a dominant immunosuppressive axis where TIGIT signaling from malignant cells via CD112 to CD8+ T cells promotes TIGIT+CD8+ T cell enrichment after anti-HER2 therapy and correlates with poor outcomes. Therapeutically, restoring CD226 on CD8+ T cells and/or combining anti-TIGIT with anti-HER2 reprogrammed anti-tumor immunity, overcoming TIGIT-refractory resistance.

Zhang L, Li J, Xiu B et al. · Cell death & disease · (2026) · View on PubMed ↗

Multiple organ dysfunction syndrome: molecular mechanisms and therapeutic strategies.

This review summarized the molecular mechanisms underlying multiple organ dysfunction syndrome (MODS) and discussed therapeutic strategies in the context of severe insults such as infection, trauma, pancreatitis, shock, and burns. It highlights that MODS pathogenesis involves dynamic, multi-level interactions including inflammation, microcirculatory dysfunction, coagulation abnormalities, cell death, and DNA damage. The synthesis supports a shift toward organ-specific injury frameworks and informs future multi-target therapeutic development in critical care.

Xu X, Chen J, Feng Y et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗

RBM20 variants disrupt Ca2+ handling and metabolism in dilated and non-compaction cardiomyopathy stem cell models.

The study examined how RBM20 variants (notably R634L and R634W) disrupt Ca2+ handling and metabolism in dilated cardiomyopathy (DCM) and left ventricular non-compaction (LVNC) using patient-derived iPSC-derived cardiomyocytes, 3D cardiospheres, engineered myocardial tissues, and CRISPR/Cas9 isogenic rescue/mutation-insertion lines. RBM20 mis-localization and splicing defects were linked to altered cardiomyocyte functional phenotypes, providing mechanistic insight into phenotype variability across RBM20 mutation carriers. These findings advance genotype-to-cell-function mapping for RBM20 cardiomyopathy and support more personalized therapeutic approaches beyond HFrEF.

Rebs S, Sedaghat-Hamedani F, Kayvanpour E et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗

Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.

The study assessed the real-world post-marketing safety profile of tirzepatide, a dual GIP/GLP-1 receptor agonist, using FAERS pharmacovigilance reports where tirzepatide was the primary suspected drug (Q2 2022–Q4 2025). Disproportionality analyses using ROR, PRR, IC, and EBGM, along with time-to-onset and comparative analyses versus semaglutide, were used to identify and characterize safety signals. This provides clinically relevant surveillance evidence to refine risk-benefit understanding of tirzepatide in routine practice.

Guo X, Zhang J, Li Q et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗

Precision omic portrait deciphers the epigenetic variable during cellular identity reshaping of metastatic head and neck squamous cell carcinoma.

This study integrated single-cell RNA sequencing from 12 primary lesions, 12 lymphatic metastases, and 12 distant metastases to map pan-metastatic cellular identity reshaping in metastatic head and neck squamous cell carcinoma (HNSCC). As metastasis progressed, the proportion of cancer-associated fibroblasts (CAFs) increased markedly, and the authors used spatiotemporal RNA alternative splicing and trajectory tracing to characterize epigenetic/identity-variable programs during lineage evolution. These findings suggest that metastasis-associated epigenetic splicing and trajectory states—especially CAF expansion—may provide actionable biomarkers or targets to limit metastatic plasticity in HNSCC.

Feng Q, Shan X, Xia Y et al. · Science bulletin · (2026) · View on PubMed ↗

Immune-Related Adverse Events From Checkpoint Inhibitors: An Evidence-Based Management Review.

This evidence-based management review studied treatment strategies for immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs) across organ systems. It reports that corticosteroids are first-line (with ~70–85% remission for many grade 2 toxicities using oral prednisone 0.5–1 mg/kg/day and grade 3–4 using IV methylprednisolone 1–2 mg/kg/day), while 20–40% of severe irAEs are steroid-refractory requiring rapid escalation with organ-directed therapies such as mycophenolate, infliximab/vedolizumab, IVIG/plasma exchange, and investigational abatacept for myocarditis. Clinically, the review provides a practical escalation framework to reduce morbidity and mortality from ICI toxicities.

Petrelli F, Dottorini L, Rossitto M et al. · Critical reviews in oncology/hematology · (2026) · View on PubMed ↗

Long-term incidence of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.

This population-based cohort study examined long-term hepatocellular carcinoma (HCC) incidence after hepatitis B surface antigen (HBsAg) seroclearance in adults with chronic hepatitis B (CHB) in Hong Kong. Using a territory-wide database for patients who cleared HBsAg between 2000 and 2022 (n=13,379) and comparing age- and sex-specific HCC rates to the general population, it found that HCC still occurred after seroclearance (with 274 cases reported in the truncated results). The scientific and clinical significance is that it quantifies residual HCC risk after HBsAg loss, informing how long surveillance should continue even after seroclearance.

El-Debeiky S, Hiu-Fung Lam T, Sze-Man Lai M et al. · Gastroenterology · (2026) · View on PubMed ↗

Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

This phase 3 randomized, double-blind, placebo-controlled trial studied the efficacy and safety of dabrafenib plus trametinib in adults with radioactive iodine-refractory BRAFV600E-positive differentiated thyroid cancer. The trial enrolled previously treated patients aged ≥18 years with locally advanced or metastatic disease and compared the combination against placebo in a global study design. Clinically, the results address whether dual BRAF/MEK inhibition improves outcomes for a targeted subgroup with limited options after radioactive iodine failure.

Gao M, Park YJ, Lin CC et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

SERENA-6 prospectively monitored circulating tumor DNA (ctDNA) in patients with hormone receptor-positive advanced breast cancer receiving first-line aromatase inhibitor plus CDK4/6 inhibitor, to detect emergence of an acquired ESR1 mutation and trigger therapy switching to camizestrant. Switching to camizestrant at the point of ESR1 mutation emergence (before clinical progression) improved progression-free survival, with the extended analysis reporting comprehensive ESR1 surveillance results. This supports ctDNA-guided, mutation-timed endocrine therapy escalation as a clinically actionable strategy to delay progression in ESR1-mutant disease.

Turner NC, Mayer EL, Park YH et al. · The Lancet. Oncology · (2026) · View on PubMed ↗

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) 2025 international guidelines for the management of patients with obsessive-compulsive disorder.

These CANMAT/ICOCS 2025 international guidelines synthesized evidence on interventions for obsessive-compulsive disorder (OCD) across the lifespan for clinicians worldwide. The key finding is that the guideline provides updated, structured recommendations covering efficacy, safety, and tolerability of the full range of OCD treatments based on systematic literature review. This is clinically significant because it standardizes evidence-based OCD management to support consistent decision-making in routine practice.

Van Ameringen M, Fineberg NA, Ravindran A et al. · Journal of psychiatric research · (2026) · View on PubMed ↗

Platelet-Activating Anti-Platelet Factor 4 Disorders.

This review studied platelet-activating anti-platelet factor 4 (PF4) disorders in humans, focusing on heparin-induced thrombocytopenia (HIT) and related immune-mediated syndromes including vaccine-induced immune thrombocytopenia and thrombosis (VITT). The key finding is that PF4 antibodies drive highly prothrombotic, thrombocytopenic disease via PF4–polyanion interactions, with distinct triggers (heparin, nonpharmacologic polyanions, or adenoviral-vector vaccines) and antibody properties that explain atypical clinical presentations. This is scientifically and clinically significant because it clarifies mechanism-based differences that guide diagnosis and treatment of these high-risk thrombotic conditions.

Warkentin TE, Greinacher A · The New England journal of medicine · (2026) · View on PubMed ↗

Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.

This double-blind, randomized, placebo-controlled phase 2 trial studied the oral OGA inhibitor ceperognastat in participants with early symptomatic Alzheimer disease (AD) with biomarker evidence of tau pathology. The key finding is that the trial evaluated ceperognastat’s efficacy and safety with the primary outcome restricted to early symptomatic AD patients showing tau pathology (low-to-moderate tau burden as defined in the study). This is clinically significant because targeting O-linked N-acetylglucosaminidase (OGA) is a tau-aggregation strategy that could modify disease course if efficacy and tolerability are demonstrated.

Fleisher AS, Munsie L, Mancini M et al. · JAMA · (2026) · View on PubMed ↗

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

This individual participant data meta-analysis studied amyloid PET quantitation in humans by collecting Centiloid values across studies and comparing data-driven positivity cutoffs with visual reads. The key finding is that robust Centiloid thresholds can be derived to standardize amyloid PET interpretation, addressing variability caused by different methods and cutoffs. This is clinically significant because standardized Centiloid positivity improves diagnostic consistency and supports eligibility decisions for amyloid-targeting therapies.

Blazhenets G, Soleimani-Meigooni DN, Chiotis K et al. · JAMA · (2026) · View on PubMed ↗

Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.

The CRAVE study prospectively observed adults with obesity initiating semaglutide or tirzepatide to assess changes in food cravings, diet quality, dietary intake, and body composition over 24 weeks using food records, HEI-2020, the Food Cravings Inventory-III, and bioelectrical impedance analysis. The key finding is that GLP-1 receptor agonist–based obesity management was associated with measurable changes in these diet- and body-composition–related outcomes during real-world treatment. This is clinically significant because it links GLP-1 RA therapy to behavioral and nutritional phenotypes that may influence adherence and long-term weight management.

Babazadeh D, Therrien S, Fitch AK et al. · Obesity pillars · (2026) · View on PubMed ↗

Eosinophil subtypes in asthmatic patients treated with mepolizumab, omalizumab and dupilumab.

This prospective 52-week study evaluated eosinophil subtypes—resident (rEos) and inflammatory (iEos)—in 82 patients with severe asthma treated with mepolizumab, dupilumab, or omalizumab (and compared with biologic-naïve controls). The key finding is that different asthma biologics differentially affect the proportions of rEos and iEos over time, reflecting distinct immunologic mechanisms. This is clinically significant because eosinophil-subtype dynamics may help refine biomarker-driven selection and monitoring of biologic therapy in severe asthma.

Cabrera López C, Sánchez Santos A, Lemes Castellano A et al. · ERJ open research · (2026) · View on PubMed ↗

Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system.

This real-world pharmacovigilance study analyzed FDA Adverse Event Reporting System (FAERS) data to compare adverse event signals for the anti-amyloid monoclonal antibodies lecanemab versus donanemab. The key finding is that disproportionality analyses (including sex-stratified and sensitivity analyses) were used to identify and contrast post-marketing adverse event reporting profiles between the two drugs. This is clinically significant because it informs risk-benefit discussions and post-marketing safety surveillance for anti-amyloid therapies.

Feng X, Bi S, Shi C et al. · Frontiers in pharmacology · (2026) · View on PubMed ↗

A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

This randomized, nivolumab-controlled phase 2 trial studied the bispecific antibodies lomvastomig (PD-1/TIM-3) and tobemstomig (PD-1/LAG-3) versus nivolumab in CPI-naïve patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) who were refractory or intolerant to one prior chemotherapy line. The key finding is that the study design and biomarker/pharmacodynamic assessments were used to compare overall survival and secondary efficacy endpoints across the three arms. This is clinically significant because it tests whether dual checkpoint targeting (TIM-3 or LAG-3 alongside PD-1) improves outcomes beyond standard PD-1 blockade in a defined, previously treated ESCC population.

Wyrwicz L, Dechaphunkul A, Lee JS et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

This study investigated whether ctDNA tumor fraction (TF) from plasma cell-free DNA assessed by hybrid-capture next-generation sequencing can select immunotherapy-based regimens in advanced non-small cell lung cancer (aNSCLC). The key finding is that TF’s predictive and prognostic value was evaluated using a nationwide US clinicogenomic database (and an independent cohort), aiming to improve patient selection beyond imperfect biomarkers like PD-L1. This is clinically significant because ctDNA TF could enable more precise treatment intensification decisions, potentially sparing non-benefiting patients from added chemotherapy.

Dall’Olio FG, Zrafi W, Vasseur D et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

This single-arm phase I trial studied the combination of avutometinib (dual RAF/MEK inhibitor), abemaciclib (CDK4/6 inhibitor), and fulvestrant in patients with HR+/HER2− metastatic breast cancer previously treated with a CDK4/6 inhibitor. The key finding is that the trial’s primary objective was to determine the maximum tolerated dose (MTD) using planned abemaciclib dose levels alongside avutometinib and fulvestrant in this resistant population. This is clinically significant because it tests a rational MAPK-pathway–targeting strategy to overcome CDK4/6 inhibitor resistance in a clinically defined, heavily pretreated group.

Waks AG, Segui E, Li T et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

This translational research platform analyzed FGFR-altered solid tumors in patients treated with selective FGFR inhibitors (FGFRi), combining retrospective/longitudinal clinical sampling with patient-derived xenografts (PDX) to study efficacy and resistance mechanisms. The work characterized how different FGFR amplifications and mutations (including beyond known activating variants) relate to FGFRi sensitivity and resistance, using genomic, transcriptomic, and proteomic profiling to define predictive signals. The study supports development of more precise biomarker strategies for selecting FGFR-targeted therapy and anticipating resistance across multiple FGFR-altered tumor types.

Hierro C, Sánchez-Guixé M, Tarcic G et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effects.

This observational analysis tested whether circadian genotypes in PER3 interact with the time of day of prostate cancer external beam radiotherapy to influence risk of late side-effects in the multinational REQUITE cohort (n=1760). The study found that specific PER3 circadian genotypes modify the association between radiotherapy timing and subsequent late toxicity risk. These results support the concept of genetically guided chronomodulation to reduce radiotherapy side-effects while maintaining efficacy.

Webb AJ, Harper E, Rattay T et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer immunotherapy & immune microenvironments (ICI, CAR-T, checkpoint axes)

Single-cell and spatial transcriptomic analysis reveal distinct tumor microenvironment signatures in primary and recurrent hypopharyngeal squamous cell carcinoma.

The study analyzed primary versus recurrent hypopharyngeal squamous cell carcinoma (HPSCC) tumor microenvironments in patients (n=6 primary, n=3 recurrent) using single-cell RNA sequencing and spatial transcriptomics. It revealed distinct TME signatures and recurrence-associated regulatory networks that differ between primary and recurrent tumors. These results improve mechanistic understanding of HPSCC recurrence and may guide development of recurrence biomarkers or targeted therapies.

Cai Z, Zhang J, Ding Y et al. · Cellular & molecular biology letters · (2026) · View on PubMed ↗

Tumor innervation drives cancer cell plasticity and immune evasion through the SLPI-GZMB axis.

This work studied how tumor innervation regulates cancer cell plasticity and immune evasion using paired murine intraneural versus nonintraneural tumor models combined with single-cell RNA sequencing, and it validated relevance in human tumors with perineural invasion. Nerve-associated cancer cells showed increased secretory leukocyte protease inhibitor (SLPI), which was induced by sensory neuron-derived substance P acting through tumor cell TACR1; SLPIhigh cells were enriched for WNT/β-catenin programs and linked to immune escape via the SLPI–GZMB axis. These findings identify the SLPI–GZMB pathway and TACR1/SP signaling as mechanistic targets to disrupt perineural, immune-evasive tumor states.

Zhang H, Wu Q, Wang L et al. · Cancer letters · (2026) · View on PubMed ↗

Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial.

This single-arm phase II trial studied spatial tumor and draining lymph node immune microenvironments in 22 patients with resectable non-small cell lung cancer (NSCLC) treated with neoadjuvant pembrolizumab plus platinum chemotherapy, followed by surgery and adjuvant immunotherapy. Digital spatial profiling revealed divergent immune microenvironment patterns associated with major pathological response (MPR) and treatment outcomes. These findings suggest that spatial immune features could serve as biomarkers to predict response to neoadjuvant chemoimmunotherapy in resectable NSCLC.

Chen M, Li R, Cheng Z et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

---

Targeted oncology (specific oncogenic pathways/drug targets)

An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

This phase 1 first-in-human clinical trial studied DYP688, an anti-PMEL (PMEL17/gp100) antibody-drug conjugate delivering the Gq/11 inhibitor SDZ475, in patients with metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas. The key finding was that the trial design and early results assessed safety as the primary endpoint and pharmacokinetics plus preliminary antitumor activity as secondary endpoints in 66 enrolled patients (full efficacy details truncated). This work is clinically significant because it targets the high-frequency GNAQ/GNA11-mutant biology of uveal melanoma using a lineage antigen–directed ADC strategy.

Carlino MS, Kapiteijn E, Piperno-Neumann S et al. · Nature medicine · (2026) · View on PubMed ↗

Targeting LIG1 to overcome oxaliplatin resistance by inducing PANoptosis in colorectal cancer.

This study investigated whether targeting DNA ligase 1 (LIG1) can overcome oxaliplatin resistance in colorectal cancer by inducing PANoptosis. Through screening a library of 1220 natural compounds, the authors identified gambogenic acid (GNA) as a selective LIG1-binding inhibitor and showed that LIG1 inhibition sensitized colorectal cancer to oxaliplatin via PANoptosis-related mechanisms. The findings position LIG1 and GNA as candidate therapeutic strategies to counteract platinum resistance in CRC.

Gao Q, Chen M, Ling H et al. · Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · (2026) · View on PubMed ↗

---

Clinical oncology trials & treatment optimization (phase I–III, peri/post-progression strategies)

Colorectal anastomotic safety assessment using ICG fluorescence and flexible endoscopy (COLOSSEUM): a global survey of 1367 surgeons.

This global survey studied colorectal surgeons’ real-world use of indocyanine green (ICG) fluorescence and flexible endoscopy (FE) for anastomotic safety assessment, enrolling 1367 surgeons from 80 countries. It quantified practice patterns and intersurgeon variability to highlight how ICG/FE are implemented across institutions. The findings can inform standardized recommendations to reduce anastomotic leakage risk and harmonize perioperative assessment practices.

Belvedere A, Licardie E, Sochorova D et al. · Surgical endoscopy · (2026) · View on PubMed ↗

BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.

This phase 1b trial evaluated the BCL-2/BCL-xL inhibitor pelcitoclax given with osimertinib in patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), stratified into three cohorts by prior TKI exposure and chemotherapy. The key reported outcome was the safety profile and preliminary antitumor activity of the combination across TKI-resistant and TKI-naïve settings. Clinically, combining pelcitoclax with osimertinib targets apoptosis resistance pathways to potentially improve outcomes in EGFR-mutated advanced NSCLC where osimertinib alone is insufficient.

Ma Y, Wu C, Zhao YQ et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗

Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial.

In the Phase II ACT-GI trial, investigators randomized U.S. patients with gastrointestinal cancers and persistent chemotherapy-induced thrombocytopenia (platelets ≤85×10^9/L on day 1 despite adequate recovery time) to avatrombopag versus placebo. Avatrombopag significantly improved successful correction of thrombocytopenia and reduced recurrence compared with placebo as the primary endpoint. This supports avatrombopag, a thrombopoietin receptor agonist, as a potential targeted oral option to manage persistent CIT and help maintain chemotherapy delivery.

Al-Samkari H, Shatzel JJ, Panch SR et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.

This ASCO Living Guideline (Version 2026.1.0) synthesized evidence to provide recommendations for systemic treatment of recurrent high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer. The key finding is the guideline’s structured, evidence-based treatment framework derived from 147 eligible RCTs/systematic reviews (36 directly informing recommendations) to guide therapy selection by clinical scenario. Clinically, it standardizes decision-making for recurrent disease management and updates ongoing practice as new evidence emerges.

Lesnock JL, Temin S, Bouberhan S et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

The ORCHARD phase II study evaluated post-progression therapy in patients with EGFR-mutated advanced NSCLC who developed resistance after first-line osimertinib, specifically focusing on the EGFR C797X resistance mutation. In the osimertinib plus gefitinib module, the combination of osimertinib 80 mg daily with gefitinib 250 mg daily produced measurable anti-tumor activity assessed by investigator RECIST 1.1 objective response rate. This provides clinically relevant evidence for targeting a known osimertinib resistance mechanism (EGFR C797X) with dual EGFR inhibition after progression.

Goldberg SB, Ahn MJ, Baik C et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

---

Hematologic malignancies (AML/MDS/ET/MM and related trials)

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

This retrospective prognostic study analyzed 241 patients with triple-negative essential thrombocythemia (TN-ET) using myeloid panel sequencing and confirmatory bone marrow biopsy to assess how mutational profiles and cardiovascular risk factors relate to outcomes. Pathogenic/likely pathogenic variants were present in 19.5% of patients, and mutation carriers had older age and higher prior thrombosis frequency, with variant presence associated with leukemic progression (HR 12.608) and worse overall survival (HR 3.008; additional CI details truncated). The findings are significant for risk stratification in TN-ET, supporting more tailored treatment decisions based on genomic risk.

Carreño-Tarragona G, Gil-Manso R, Hernández-Boluda JC et al. · Leukemia · (2026) · View on PubMed ↗

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

The Phase III ENHANCE study evaluated whether adding the CD47-targeted antibody magrolimab to azacitidine improves outcomes versus placebo plus azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndromes (intermediate- to very-high-risk by IPSS-R). The key finding was that magrolimab plus azacitidine improved clinical efficacy compared with azacitidine alone while maintaining a manageable safety profile. This trial informs a potential new chemoimmunotherapy backbone for untreated higher-risk MDS by targeting CD47-mediated immune evasion.

Sallman DA, Garcia-Manero G, Daver N et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

---

Cardiovascular disease & lipid management

Evolocumab in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis of efficacy and safety.

This systematic review and meta-analysis evaluated evolocumab, a PCSK9 inhibitor, for efficacy and safety in patients with atherosclerotic cardiovascular disease (ASCVD), incorporating data through recent long-term extension studies and subgroup populations. The analysis synthesized evidence on LDL-C lowering and clinical outcomes while updating the safety profile across diverse ASCVD subgroups. Clinically, the work provides an updated evidence base for using evolocumab to reduce cardiovascular risk and to inform risk–benefit decisions in real-world ASCVD populations.

Li S, Zhang C, Liu Y · BMC cardiovascular disorders · (2026) · View on PubMed ↗

Procedural Strategies for Optimal Transcatheter Aortic Valve Replacement: An International Position Statement.

This international position statement studied procedural optimization strategies for transcatheter aortic valve replacement (TAVR), focusing on maintaining coronary access and avoiding permanent pacemaker implantation while improving valve durability. It highlights the TAVR CODE framework using four fluoroscopic parameters—coaxiality, orientation, depth, and expansion—to standardize assessment of optimal transcatheter heart valve (THV) implantation. Scientifically and clinically, adopting these standardized fluoroscopic targets is expected to improve THV performance and reduce implantation-related complications.

Maznyczka A, Pilgrim T, Hildick-Smith D et al. · JACC. Cardiovascular interventions · (2026) · View on PubMed ↗

---

Diabetes, obesity & cardiometabolic pharmacology (GLP-1/GIP/SGLT2/DPP4, insulin de-escalation)

Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.

This systematic review and meta-analysis studied the effect of tirzepatide, a GLP-1/GIP receptor agonist, on cardiovascular outcomes and mortality in adults with overweight/obesity or type 2 diabetes mellitus (T2DM). It pooled randomized controlled trials with at least 24 weeks of follow-up (search through January 14, 2026) and used fixed-effects meta-analysis plus trial sequential analysis to evaluate whether evidence supports definitive conclusions. The clinical significance is that it synthesizes whether tirzepatide provides cardiovascular and survival benefits beyond glycemic control in high-risk metabolic populations.

Spiazzi BF, Zingano CP, Colpani V et al. · Diabetes research and clinical practice · (2026) · View on PubMed ↗

The ARDS, Pneumonia, and Sepsis (APS) Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes.

The APS Consortium paper studied the rationale, design, and feasibility of a national NIH platform to phenotype acute respiratory distress syndrome (ARDS), pneumonia, and sepsis in critically ill adults. It describes a multicenter longitudinal prospective observational cohort study (Phenotyping Study) planned to enroll 4,000 patients with ARDS, pneumonia, and/or sepsis to generate biospecimens and data for biological characterization. This platform is significant because it aims to accelerate therapeutic development by enabling standardized, high-resolution phenotyping of critical illness syndromes.

Self WH, Calfee CS, Brown SM et al. · Chest · (2026) · View on PubMed ↗

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.

Using a target trial emulation approach with a large U.S. claims database (2017–2022), this study compared ischemic optic neuropathy risk among adults with type 2 diabetes initiating GLP-1 receptor agonists versus SGLT2 inhibitors or DPP4 inhibitors. The analysis estimated the relative risk of nonarteritic anterior ischemic optic neuropathy (NAION/ION) associated with each drug class. The findings aim to clarify medication safety for GLP-1RAs regarding NAION risk in real-world diabetic populations.

Reynolds KR, O’Malley KM, Roy JA et al. · Annals of internal medicine · (2026) · View on PubMed ↗

Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.

This target trial emulation compared rates of insulin discontinuation in U.S. Veterans with type 2 diabetes receiving basal insulin who initiated a GLP-1 receptor agonist versus an SGLT-2 inhibitor or a DPP-4 inhibitor between 2020 and 2022 using Veterans Health Administration EHR data. The study found that initiating a GLP-1 receptor agonist was associated with higher rates of insulin discontinuation than initiating oral agents (SGLT-2 inhibitors or DPP-4 inhibitors), after adjustment via the emulation approach. These findings support GLP-1RA-based intensification as a strategy to reduce insulin dependence in basal-insulin-treated T2D patients in routine clinical practice.

Lipska KJ, Zawack K, Yan L et al. · Annals of internal medicine · (2026) · View on PubMed ↗

Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.

This nationwide Swedish register-based cohort study examined whether initiating GLP-1 receptor agonists increases risk of nonarteritic anterior ischemic optic neuropathy (NAION) among GLP-1RA initiators compared with SGLT-2 inhibitor initiators from 2013 to 2024. Using propensity score weighting, the authors found no clinically meaningful increase in NAION risk with GLP-1RA use relative to SGLT-2 inhibitors. The results help address safety concerns about GLP-1RAs and NAION and inform risk–benefit discussions for patients starting these therapies.

Ueda P, Svanström H, Söderling J et al. · Annals of internal medicine · (2026) · View on PubMed ↗

Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape.

This narrative review summarized how treatment of HER2-positive breast cancer has evolved across metastatic and early-stage settings, focusing on the changing therapeutic landscape over the past three decades. The key finding is that modern HER2-directed strategies have shifted outcomes from poor survival (median <2 years in metastatic disease historically) to substantially longer survival with increasing proportions of patients living beyond 5 years and with altered patterns of presentation (including more de novo metastatic disease). Clinically, this synthesis frames current management decisions and highlights how ongoing advances in HER2-targeted therapy are reshaping prognosis and treatment sequencing.

Lipsyc-Sharf M, Hurvitz SA · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · (2026) · View on PubMed ↗

GLP-1 Receptor Agonists and Fertility: What Is Known So Far?

This narrative review summarized evidence on GLP-1 receptor agonists (including liraglutide and semaglutide) and fertility outcomes, with emphasis on women with polycystic ovary syndrome (PCOS) and infertility. The authors found consistent metabolic improvements and emerging clinical trial evidence of improved reproductive outcomes in PCOS, such as increased menstrual regularity, ovulation, and pregnancy rates. The review supports considering GLP-1RAs as an adjunct in preconception care for selected patients with PCOS, while highlighting the need for further reproductive-outcome research.

Becker AS, Castilhos JP, Shugair SAS et al. · JBRA assisted reproduction · (2026) · View on PubMed ↗

---

Neurology & neurodegeneration (AD/CTE/biomarkers, brain aging, neuroinflammation)

Spatial mapping and senolytic targeting of senescent and disease-associated microglia in aged mouse brain white matter.

The study mapped senescent and disease-associated microglia (DAM) in naturally aged mouse brain white matter using regional gene expression profiling, immunolabeling, GeoMx digital spatial profiling, and CosMx spatial molecular imaging. It identified an aged brain–exclusive microglial population concentrated in white matter (notably the fimbria) expressing DAM genes together with a “SenBrain” senescence signature including galectin-related programs. These spatially resolved findings suggest that targeting senescent/DAM microglia in vulnerable white-matter niches could help mitigate late-life cognitive decline.

Carver CM, Gomez PT, Rodriguez SL et al. · Nature aging · (2026) · View on PubMed ↗

Brain mitochondria as key drivers of cognition and behaviour.

This Nature Reviews Neuroscience article synthesized evidence that brain mitochondria are key drivers of cognition and behavior by shaping neuronal and glial circuit function. It highlights mitochondrial roles in bioenergetic support, Ca2+ dynamics, reactive oxygen species regulation, neurotransmitter synthesis/turnover, and quality control programs that preserve cellular integrity. The review is significant because it links mitochondrial plasticity and dysfunction to circuit-level variability underlying behavioral outputs.

Sandi C, Lobo MK, Hollis F et al. · Nature reviews. Neuroscience · (2026) · View on PubMed ↗

Large-scale multi-sequence pretraining for generalizable MRI analysis in versatile clinical applications.

This study presented MARS, a large-scale MRI foundation model trained with a pretraining strategy designed to disentangle anatomy-invariant features from sequence-specific variation for generalizable clinical analysis. Trained on 64 datasets spanning 10 anatomical structures and multiple MRI sequences (including 336,476 volumetric scans from 34 datasets), the model aims to improve robustness across heterogeneous MRI acquisition settings (full downstream results truncated). This is scientifically and clinically significant because it addresses MRI heterogeneity barriers to deploying deep learning models across diverse real-world clinical applications.

Qiu Z, Wang X, Xie Z et al. · Nature biomedical engineering · (2026) · View on PubMed ↗

International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) study.

This study developed and validated the Lupus Brain Fog Severity Scale (LBFSS), a lupus-specific patient-reported outcome measure for cognitive symptoms in people with systemic lupus erythematosus (SLE). Using a multi-step international process with thematic analysis of patient free-text responses and iterative refinement, the finalised LBFSS demonstrated validity for assessing brain fog severity. The resulting PROM enables standardized measurement of cognitive symptoms in SLE, supporting both clinical trials and patient-centered care.

Arnaud L, Piga M, Pons-Estel GJ et al. · Lupus science & medicine · (2026) · View on PubMed ↗

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

LatAm-FINGERS studied a culturally adapted, multidomain lifestyle intervention in at-risk older adults aged 60–77 years across 11 Latin American countries using a single-blind, multicentre, randomized controlled trial design. The trial evaluated feasibility and effects on global cognitive function compared with control. If effective, this would provide regionally relevant evidence that multidomain lifestyle programs can help delay cognitive decline in Latin American populations under-represented in dementia prevention research.

Crivelli L, Suemoto CK, Sosa AL et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Control of walking direction by descending and dopaminergic neurons in Drosophila.

This research characterized neuronal populations that control walking direction at different hierarchical levels in Drosophila, focusing on descending and dopaminergic circuits. Using in vivo electrophysiological recordings and functional analyses, the authors identified two neuron populations that differentially regulate distinct aspects of walking direction. The work advances understanding of how descending and dopaminergic signals coordinate sensorimotor navigation in vivo.

Liessem S, Dahlhoff S, Iqbal FM et al. · Current biology : CB · (2026) · View on PubMed ↗

Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases.

This Neurology study assessed how well Alzheimer disease (AD) plasma biomarkers distinguish AD from prion diseases in patients recruited through the UK National Prion Clinic. The authors found that AD plasma biomarkers (including p-tau217 and other AD-associated measures) showed limited specificity for differentiating prion diseases from AD, with prion patients sometimes demonstrating abnormal biomarker patterns. Scientifically, the results indicate that plasma AD biomarker positivity should be interpreted cautiously in suspected prion disease presentations to avoid misdiagnosis.

Coysh T, Laban R, Veleva E et al. · Neurology · (2026) · View on PubMed ↗

Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy.

This longitudinal multicenter case-control study evaluated plasma phosphorylated tau 217 (p-tau217) in participants at risk for chronic traumatic encephalopathy (CTE) due to repetitive head impacts (RHI), and assessed whether p-tau217 could function as a beta-amyloid (Aβ) biomarker. The study also explored concordance between plasma p-tau217 and CTE neuropathology in a postmortem subsample. These results advance the scientific validation of blood-based biomarkers for detecting RHI-related neuropathology and potentially stratifying individuals for CTE risk.

Miner AE, Zetterberg H, Blennow K et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroimmunology & CNS autoimmune disease (MS/NMOSD/MOGAD, etc.)

Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results.

This report provides final long-term efficacy and safety outcomes from the CHAMPION-NMOSD trial (primary treatment period plus long-term extension) in adults with AQP4 antibody-positive neuromyelitis optica spectrum disorder treated with ravulizumab. Across the extended follow-up, ravulizumab maintained efficacy with sustained relapse prevention and an acceptable safety profile consistent with complement C5 inhibition. These final data strengthen the evidence base for long-term ravulizumab use in AQP4-Ab+ NMOSD and support durable disease control in routine practice.

Pittock SJ, Barnett MH, Bennett JL et al. · Neurology(R) neuroimmunology & neuroinflammation · (2026) · View on PubMed ↗

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

This international multicenter retrospective cohort study compared interleukin-6 receptor blockade (IL-6RB) therapy with intravenous immunoglobulin (IVIG) for relapse prevention in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The key finding was that IL-6RB was associated with relapse prevention outcomes that were evaluated against the historical IVIG-treated cohort. If confirmed prospectively, IL-6RB could become a practical, evidence-based relapse-preventive option for MOGAD where current therapies are limited.

Vilaseca A, Bilodeau PA, Gakis G et al. · JAMA neurology · (2026) · View on PubMed ↗

---

Infectious disease & parasitology (including host-pathogen immune mechanisms)

Repurposed anticancer drugs disrupt cancer-like traits of Theileria annulata and suppress Leishmania donovani.

The study screened a library of 436 FDA-approved anticancer drugs against Theileria annulata and then tested top hits for activity against Leishmania donovani, including cytotoxicity assessment in healthy human PBMCs. It identified 28 potent inhibitors at 1 µM with >50% activity and low cytotoxicity, indicating that repurposed anticancer compounds can disrupt parasite “cancer-like” host-manipulating traits. This supports drug repurposing as a practical strategy to develop new antiparasitic therapies targeting shared host signaling/metabolic dependencies.

Lareb S, Subudhi M, Suresh A et al. · Cell communication and signaling : CCS · (2026) · View on PubMed ↗

---

Immunology & inflammation mechanisms (innate/adaptive, sterile inflammation, autoimmunity)

The challenge and promise of studying human antigen-specific T cells.

This review examined the challenges and opportunities in studying human antigen-specific T cells, focusing on how rarity of antigen-specific populations and technical limitations have historically led to bulk, unselected analyses. It highlighted how antigen specificity, HLA restriction, and bystander effects complicate interpretation and how newer approaches can better resolve phenotype and function. The review’s significance is to guide experimental design and analytical strategies for more accurate mechanistic studies in viral immunity, cancer, and autoimmunity.

Farrar S, Antoun E, Knight JC et al. · Nature reviews. Immunology · (2026) · View on PubMed ↗

The perineurium integrates leptin with its sympathetic outflow to protect against obesity.

The study examined how leptin afferent signaling is integrated with sympathetic efferent outflow by the perineurium in mice, using single-cell RNA sequencing of mouse sympathetic ganglia to identify perineurial cell receptor expression. It showed that perineurial cells express leptin receptor (Lepr) and β2-adrenergic receptor (Adrb2), and that conditional knockout of Adrb2 in Lepr+ perineurial cells predisposed male mice to obesity. These findings identify a peripheral neuroanatomical circuit component that couples leptin sensing to sympathetic regulation, offering a potential target for obesity therapeutics.

Sarker G, Haberman E, Chandran A et al. · Nature metabolism · (2026) · View on PubMed ↗

Ear-nose-throat manifestations of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: a cross-sectional study.

This cross-sectional study evaluated ear, nose, and throat (ENT) manifestations in patients with granulomatosis with polyangiitis (GPA) versus eosinophilic granulomatosis with polyangiitis (EGPA) in a Saudi Arabian clinic population. Among 50 consecutive patients (35 GPA, 15 EGPA), comprehensive otologic, sinonasal, and laryngeal examinations plus audiology, imaging, and laboratory testing were used to characterize and compare ENT features between the two ANCA-associated vasculitides (full comparative results truncated). The findings are significant for improving early recognition and differential assessment of ENT involvement in GPA and EGPA.

Almogairen S, Alsaleh S, Alhabib SF et al. · Rheumatology international · (2026) · View on PubMed ↗

Flavin adenine dinucleotide is an endogenous suppressor for cytosolic DNA and RNA sensors to modulate innate immunity.

This mechanistic study investigated how the endogenous metabolite flavin adenine dinucleotide (FAD) regulates innate immune sensing of cytosolic DNA and RNA. FAD directly bound the catalytic pockets of cGAS and RIG-I to suppress their activity, preventing self-nucleic-acid–driven sterile inflammation and maintaining immune homeostasis, while FAD synthase (FLAD1) deficiency exacerbated auto-inflammation. These findings identify FAD as an endogenous “molecular brake” on cGAS–RIG-I pathways, suggesting potential immunomodulatory strategies for autoinflammatory disease.

Wang Y, Shen Y, Liu J et al. · Immunity · (2026) · View on PubMed ↗

MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion.

This study examined how MEK-dependent bioenergetic demand contributes to terminal exhaustion of CD8+ T cells during chronic antigen stimulation. Chronic TCR engagement increased ATP demand, drove mitochondrial NADH accumulation and reactive oxygen species, and mitochondrial dysfunction; importantly, inhibiting MEK reduced nutrient uptake and NADH accumulation and restored proliferation, thereby reducing terminal T cell exhaustion. The results support MEK inhibition as a potential therapeutic approach to prevent or reverse exhaustion in settings of persistent antigen exposure.

Mitra T, Rahman J, Hwee M et al. · Immunity · (2026) · View on PubMed ↗

Polygonatum sibiricum polysaccharide ameliorates intestinal barrier dysfunction in aging mice via gut microbiota-metabolite modulation and TLR4/NF-κB pathway inhibition.

This in vivo and in vitro study tested whether Polygonatum sibiricum polysaccharide (PSP) ameliorates age-related intestinal barrier dysfunction in aging mice. PSP improved intestinal barrier integrity by modulating the gut microbiota and its metabolites and inhibiting the TLR4/NF-κB signaling pathway. These results suggest a microbiota-metabolite–immune mechanism by which PSP could protect against aging-associated gut barrier decline.

Guan P, Zeng X, Li Z et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗

Physical activity for the management of obesity in children up to the age of 9 years.

This Cochrane systematic review synthesized evidence on physical activity interventions for managing obesity in children up to age 9 years, focusing on benefits and harms rather than prevention. The review assessed outcomes across included studies to determine whether physical activity improves obesity-related measures and what adverse effects may occur. The findings inform clinical and public-health guidance on using physical activity as a management strategy for pediatric obesity.

Loaiza-Betancur AF, Iglesias Gonzalez LE, Chavez Guapo N et al. · The Cochrane database of systematic reviews · (2026) · View on PubMed ↗

Vitamin K Prophylaxis in Newborns and Bleeding in Infancy.

This nationwide Swedish cohort study evaluated temporal trends in newborn intramuscular vitamin K prophylaxis and examined whether changes in prophylaxis uptake were associated with bleeding diagnoses during infancy up to 6 months of age. The analysis linked patterns of vitamin K administration with subsequent infant bleeding outcomes, addressing concerns about increasing parental refusal. The results have direct public health significance for policies and communication strategies to prevent vitamin K deficiency bleeding.

Simatou E, Tsamantioti E, Hallström A et al. · JAMA pediatrics · (2026) · View on PubMed ↗

Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy.

Using a target trial framework with linked electronic health records from a single academic center, this study compared neonatal outcomes after SSRI continuation versus SSRI discontinuation during pregnancy, focusing on congenital anomalies (periconception trial) and nonanomaly outcomes (early-pregnancy trial). The key finding was the estimated difference in neonatal risks between SSRI continuation and discontinuation groups while reducing confounding through the target trial approach. This provides more actionable safety evidence for clinicians and patients weighing SSRI use during pregnancy.

Aref L, Hughey JJ, Shirazi S et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

---

Respiratory disease (asthma/ARDS/severe lung conditions)

Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives.

This Circulation review outlined major milestones and future directions in pulmonary arterial hypertension (PAH), integrating advances in pathobiology, diagnosis, and treatment. The key finding is that improved understanding of PAH mechanisms—spanning endothelial dysfunction, smooth muscle proliferation, inflammation, and dysregulated signaling pathways (prostacyclin, nitric oxide, endothelin-1, and bone morphogenetic/TGF-β)—has translated into better patient outcomes over the past four decades. Scientifically, it frames ongoing research priorities for next-generation therapies and more precise diagnosis to further reduce morbidity and premature death in PAH.

Humbert M, Zeder K, Kovacs G et al. · Circulation · (2026) · View on PubMed ↗

---

Cystic fibrosis & reproductive health

The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis.

This study examined how sweat chloride measurements relate to restoration of CFTR protein function in people with cystic fibrosis treated with CFTR modulators. Key findings were that sweat chloride reduction correlates with CFTR functional restoration across modulators and study populations, and that both the magnitude of reduction and the absolute sweat chloride level are informative. Clinically, sweat chloride can serve as a practical biomarker for CFTR modulator effectiveness and expected lung benefit in CF care.

Zemanick ET, Graeber SY, Castellani C et al. · The Lancet. Respiratory medicine · (2026) · View on PubMed ↗

Reproductive health guidance for the cystic fibrosis community: a Cystic Fibrosis Foundation Position Paper.

This Cystic Fibrosis Foundation Position Paper reviewed evidence to provide reproductive health guidance for individuals with cystic fibrosis, including fertility, contraception, preconception, pregnancy, and lactation with attention to CFTR modulator exposure. The paper recommends standardized reproductive health services with education starting at diagnosis and revisited annually, and summarizes safety considerations for contraception and CFTR modulator use around conception and during pregnancy/lactation. Scientifically and clinically, it aims to harmonize counseling and care pathways to improve reproductive outcomes in the CF community.

Jain R, Taylor JL, Kazmerski TM et al. · The Lancet. Respiratory medicine · (2026) · View on PubMed ↗

---

Kidney disease & spatial pathology/omics

Next-generation kidney tissue analysis - spatial omics and digital pathology.

This Nature Reviews Nephrology article reviewed next-generation kidney tissue analysis approaches, emphasizing spatial omics and digital pathology to overcome limitations of non-spatial single-cell methods. It argues that spatially resolved measurements are crucial for understanding cellular localization, tissue organization, and cell–cell interactions that drive kidney disease processes. The review is significant because it frames how integrating spatial omics with digital pathology can improve diagnosis, prediction, and prognostication in kidney disorders.

Yoshikawa T, Bülow RD, Boor P et al. · Nature reviews. Nephrology · (2026) · View on PubMed ↗

---

Genomics, epigenetics & genome maintenance (chromatin, cohesin, TF binding, parasites’ epigenetics)

CST complex promotes second-strand synthesis in break-induced replication.

The study investigated the role of the CST complex (Cdc13–Stn1–Ten1) in break-induced replication (BIR) in yeast cells, focusing on steps of second-strand synthesis after single-ended DNA breaks. It found that early BIR events (5’ strand resection, D-loop formation, and first-strand synthesis) proceed normally without CST, but second-strand synthesis is impaired. Scientifically, this identifies CST as a key factor specifically required for efficient second-strand synthesis during BIR, informing models of genome stability and mutagenesis.

Thakre P, Wang J, Liu L et al. · Nature structural & molecular biology · (2026) · View on PubMed ↗

Genetic architecture of lung cancer revealed by common and rare variant analyses across population-scale biobanks.

The study investigated lung cancer genetic architecture using common and rare variant analyses across population-scale biobanks, including 52,550 cases and 1,617,173 controls from three whole-genome sequencing cohorts (UK Biobank, 100,000 Genomes Project, All of Us) plus five imputed array datasets. It applied position-based single-variant testing and gene-based aggregation tests for rare and ultra-rare non-coding RNA variants to identify determinants of lung cancer risk. This work clarifies the contribution of rare non-coding variation and improves understanding of susceptibility mechanisms beyond common GWAS loci.

Zhao J, Qiao L, Zhang Y et al. · NPJ precision oncology · (2026) · View on PubMed ↗

A universal 6iL/E4 culture system for deriving and maintaining embryonic stem cells across mammalian species.

The study developed and tested a defined, serum-free embryonic stem cell (ESC) culture system (6iL/E4) in multiple mammalian species, including mouse, rat, rabbit, and bovine embryos. The authors found that 6iL/E4 supports conserved self-renewal and long-term derivation of authentic ESCs by engaging signaling modules involving GSK3α, WNT, STAT3, PDGFR, and MEK/ERK, with rabbit derivation additionally requiring the LATS inhibitor TDI-011536 (TDI). This cross-species ESC platform provides a practical, pathway-informed method to generate ESCs for comparative developmental biology and regenerative research.

Wang D, Ming H, Yang D et al. · Cell research · (2026) · View on PubMed ↗

Genome-wide profiling of histone modifications and transcription factor binding at single-cell resolution by DeChIC-seq.

The study introduced DeChIC-seq, a DNA deaminase-based chromatin immuno-conversion sequencing method, to profile histone modifications and transcription factor (TF) protein–DNA interactions at single-cell resolution. DeChIC-seq uses a protein A–DddAtox fusion to induce localized C-to-U conversions near antibody-bound chromatin, enabling genome-wide background retention without immunoprecipitation and improving detection of sparse TF binding. This technique advances single-cell epigenomics by enabling more reliable, antibody-guided mapping of TF–chromatin interactions and histone marks for mechanistic gene regulation studies.

Shi Z, Chen X, Yang Y et al. · Cell research · (2026) · View on PubMed ↗

Folding a broken genome: the versatile roles of cohesin in genome maintenance.

This Nature Reviews Genetics article examined the versatile roles of cohesin in genome maintenance, focusing on sister chromatid cohesion and interphase chromatin loop extrusion mechanisms. It highlights that cohesin-mediated sister chromatid tethering supports accurate chromosome segregation and high-fidelity homologous recombination repair, while cohesin-driven 3D loop organization is increasingly linked to DNA repair processes beyond canonical cohesion. The review synthesizes emerging evidence that cohesin’s structural genome functions directly influence genome stability, informing how defects in cohesin pathways may contribute to disease.

Marin-Gonzalez A, Ha T · Nature reviews. Genetics · (2026) · View on PubMed ↗

Cytoplasmic circular dsDNA is a key constituent of stress granules.

The study investigated the molecular composition of stress granule cores in eukaryotic cells, focusing on whether circular double-stranded DNA is present in these ~200 nm dense cores. The authors found that more than half of the nucleic acid content of stress granule cores is cytoplasmic circular dsDNA. This identifies a specific nucleic-acid constituent that may help explain how stress granules assemble and could link stress granule biology to disease states involving dysregulated membraneless organelles.

Demeshkina NA, Ferré-D’Amaré AR · eLife · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on July 15, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.